|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
immune checkpoint inhibition
|
|
gptkbp:advocates_for
|
required
|
|
gptkbp:analyzes
|
to be assigned
|
|
gptkbp:clinical_trial
|
ongoing
pending
planned
recruiting
multiple sites
available.
overall response rate
open-label
NC T03610167
|
|
gptkbp:collaborations
|
ongoing
various research institutions
|
|
gptkbp:collection
|
ongoing
|
|
gptkbp:criteria
|
defined
|
|
gptkbp:developed_by
|
Tetra Therapeutics
|
|
gptkbp:dosage_form
|
to be defined
|
|
gptkbp:duration
|
to be determined
|
|
gptkbp:first_described_by
|
gptkb:2018
|
|
gptkbp:frequency
|
once every two weeks
|
|
gptkbp:healthcare
|
not granted
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TTI-621
|
|
gptkbp:indication
|
gptkb:healthcare_organization
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
under investigation
|
|
gptkbp:is_monitored_by
|
ongoing
|
|
gptkbp:is_tested_for
|
Phase 1
under study
|
|
gptkbp:is_used_for
|
solid tumors
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:market
|
not marketed
|
|
gptkbp:moral
|
obtained
|
|
gptkbp:notable_work
|
to be published
|
|
gptkbp:objective
|
evaluate safety and efficacy
|
|
gptkbp:population
|
adults
|
|
gptkbp:products
|
submitted
|
|
gptkbp:project
|
investigational
|
|
gptkbp:publishes
|
gptkb:stock_market_index
|
|
gptkbp:receives_funding_from
|
secured
|
|
gptkbp:regulatory_compliance
|
not approved
|
|
gptkbp:related_to
|
gptkb:vaccine
|
|
gptkbp:research
|
gptkb:Company
completed
planned
defined
to be assessed
|
|
gptkbp:research_areas
|
hematology
|
|
gptkbp:research_focus
|
oncology
multidisciplinary
|
|
gptkbp:safety_features
|
in place
under evaluation
|
|
gptkbp:side_effect
|
monitored
to be determined
|
|
gptkbp:sponsor
|
Tetra Therapeutics
|
|
gptkbp:status
|
gptkb:legal_case
|
|
gptkbp:targets
|
C D47
SIR Pα
|
|
gptkbp:treatment
|
gptkb:battle
established
explored
|
|
gptkbp:type
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsParent
|
gptkb:Tessa_Therapeutics
|
|
gptkbp:bfsLayer
|
5
|